Lyderm (Permethrin) is indicated for the management of parasitic infestations affecting the skin and hair. The primary benefit is the treatment of head lice (Pediculosis capitis) and their eggs (nits), which may help support the resolution of symptoms and promote comfort. It is also available for the management of scabies, a common skin condition caused by microscopic mites (Sarcoptes scabiei). This treatment may assist in managing the intense itching, skin irritation, and specific rashes that define these conditions. Clinical scenarios of use commonly involve cases where infestations are confirmed, and targeted relief is needed to reduce symptoms and help minimize the potential for transmission to others.

---

Quick Fact: Relief for Severe Itching and Skin Irritation

Official Population Eligibility for Lyderm (Permethrin)

Regulatory documentation defines specific populations who can and cannot use topical Permethrin based on age, allergy status, and physiological state.

Contraindicated Populations (Must Not Use)

Permethrin is contraindicated and must not be used by patients with a known hypersensitivity to the active ingredient, Permethrin, to any related substance such as a synthetic pyrethroid or pyrethrin, or to any non-active component in the cream or lotion formulation. For the 1% formulation, an allergy to plants in the Asteraceae/Compositae family (e.g., chrysanthemums) is noted as a necessary precaution.

Age-Related Eligibility

Age Group	Regulatory Status
Infants (<2 months)	Safety and effectiveness have not been established (use is prohibited)
Children (≥2 months)	Approved for use in pediatric patients two months of age and older
Adults & Elderly	Approved for use under standard labeled conditions

Conditional Use in Physiological States

Use during pregnancy is permitted only if clearly needed, as the medicine is assigned former FDA Pregnancy Category B. For nursing mothers, official guidance recommends that consideration should be given to discontinuing nursing temporarily or withholding the drug while the mother is undergoing treatment.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of topical Permethrin (Lyderm) based on its low systemic absorption, which is typically less than one percent of the applied dose. This limited uptake leads to a key regulatory finding: there are no known clinically significant systemic drug-drug interactions listed in the product’s official labeling, including those involving major metabolic pathways like the CYP enzyme system.

Official Interaction Profile

Interaction Type	Regulatory Statement
Systemic PK Interactions	None known/None documented.
Food, Alcohol, Supplements	No known interactions or required restrictions.
Elderly Patients	No special interaction precautions are needed.

Procedural and Pharmacodynamic Constraint

Permethrin's only documented interaction constraint is a pharmacodynamic consideration related to other topical treatments. Official guidance notes that applying topical Corticosteroids to treat associated eczematous skin reactions immediately prior to Permethrin application may risk exacerbating the underlying parasitic infestation. Therefore, regulatory bodies advise a procedural constraint involving the timing of the application of these two topical product classes.

No combinations with systemic medicines are classified as contraindicated due to a pharmacological interaction risk.

Targeting the Arthropod Voltage-Gated Sodium Channels

Permethrin exerts its core mechanism by acting as a molecule that acts via neurotoxicity, specifically targeting voltage-gated sodium channels ( Na^+ channels) within the nerve cells of the target parasites. The drug binds specifically to these channels and modulates their function, preventing them from closing normally. This disruption leads to an uncontrolled and prolonged influx of sodium ions into the parasite's nerve axon.

---

Causal Cascade to Neuromuscular Paralysis

The failure of the sodium channels to close initiates a cascading sequence of cellular events. The sustained, excessive sodium influx results in the hyper-excitation and overstimulation of the parasite's nervous system. This leads rapidly to a loss of neuromuscular coordination, manifesting as flaccid paralysis and serving as the direct physiological consequence of the drug’s action.

---

Constraints on Mechanistic Efficacy

The drug's mechanism of action is constrained when parasites develop metabolic resistance, primarily through the increased production of detoxification enzymes, such as Cytochrome P450 monooxygenases. These enzymes rapidly inactivate the Permethrin molecule, preventing it from reaching its sodium channel target and thus reducing the degree of sodium channel overstimulation.

Permethrin, the active ingredient in Lyderm, is administered strictly via the topical route for external use only. The medicine is available in two primary strengths: a 5% cream and a 1% lotion (cream rinse), with the required usage protocol determined by the strength applied. The treatment is structured as a single application course, though a second application may be administered exactly 7 days after the first if persisting parasitic forms are detected, which constitutes the standard re-treatment interval.

---

Administration Protocol by Formulation

The official administration protocol mandates different dosing and exposure times based on the strength of the formulation used:

Formulation	Standard Adult Dosing	Mandatory Exposure Time
5% Cream	Approximately 30 grams, applied from the head/neck to the soles of the feet	8 to 14 hours before washing off
1% Lotion	Sufficient amount to saturate the hair and scalp	10 minutes before rinsing off

---

The proper use of the 1% lotion requires that it be applied to hair previously washed with a non-conditioning shampoo and towel-dried until damp. The overall procedural structure is highly dependent on adherence to the fixed duration of contact time before removal. Labeled instructions also specify high-level rules for specific groups: the medicine is approved for use in infants as young as two months of age, and the treatment protocol for both infants and older adults must include application to the scalp, temple, and forehead. The administration protocol is solely defined by these fixed, label-based parameters.

Permethrin, the active ingredient in Lyderm, is a synthetic pyrethroid widely used to treat parasitic infestations such as scabies (mite infestation) and pediculosis capitis (head lice). The medication's effect is achieved by disrupting sodium transport across the nerve cell membranes of the arthropods, which leads to paralysis and death of the parasite.

---

Efficacy and Comparative Studies

Recent clinical trials and systematic reviews continue to evaluate the effectiveness of topical permethrin. A network meta-analysis of randomized controlled trials reported that combination therapy involving permethrin and oral ivermectin was associated with the highest cure rates for scabies. When comparing single-agent treatments, permethrin cream (5%) and oral ivermectin were observed to have similar efficacy in treating scabies after two weeks of administration, although some studies reported permethrin demonstrating quicker initial results.

For head lice, evidence from some recent trials suggests that topical dimethicone may be associated with significantly higher cure rates compared to permethrin lotion (1%). The choice of treatment often needs to consider local resistance patterns.

---

Reports of Emerging Resistance

A key focus of recent research is the increasing prevalence of treatment failure with topical permethrin for scabies in various populations. Systematic reviews suggest this trend is likely due to the emergence of resistance in Sarcoptes scabiei mites. Possible factors contributing to this reduced sensitivity include genetic mutations in the mites, specifically in the voltage-gated sodium channel, and issues related to treatment adherence and application technique.

---

Tolerability

Permethrin is generally considered to be well-tolerated based on study data. Common adverse events reported in clinical trials are mild and localized, including temporary burning, stinging, itching, or redness at the application site. These symptoms are typically transient.

Key Studies & References

1. WHO Model List of Essential Medicines: Permethrin (Tolerability/General Use)

Common questions about Lyderm (Permethrin) (FAQ)

Q: What should I do if Permethrin gets into my eyes or mouth?

Permethrin is strictly for external use. Official safety documents state that contact with the eyes and mucous membranes (like the inside of the mouth) must be avoided. If the cream or lotion accidentally enters the eyes, rinsing them immediately and thoroughly with water is advised. If irritation persists or if the cream is swallowed, it is necessary to seek professional medical assistance or contact a Poison Control Center.

---

Q: How long should I wait between my first and second Permethrin treatment?

Regulatory documents define a specific re-treatment protocol. If living parasites are still observed after the first application, a second treatment may be considered. The re-treatment interval specified in the product labeling is typically 7 days after the initial application.

---

Q: How much 5% cream should an adult apply?

Official administration instructions specify a standard adult dosage for the 5% cream is approximately 30 grams. The product labeling indicates the application area generally includes all areas of the body, from the head and neck down to the soles of the feet.

---

Q: How should I properly dispose of unused Permethrin cream?

To dispose of unused or expired Permethrin, the product must not be flushed down the toilet or poured down any sink drain. Regulatory guidance strongly recommends utilizing a community drug take-back program if one is available. If a take-back program is unavailable, official guidelines recommend mixing the product with an undesirable substance, sealing it in a container, and discarding it in household trash.

---

Q: What if I accidentally swallow Permethrin cream?

Permethrin is an external topical preparation only. Official safety information strongly advises against ingestion. In the event of accidental ingestion, contacting a healthcare professional or a Poison Control Center for guidance is required.

---

Q: Can I wash my hair with regular shampoo after using the 1% lotion?

Official patient instructions for the 1% Permethrin lotion suggest that the hair should typically not be re-washed for 1 to 2 days after the initial treatment application and rinsing. This is to help ensure the treatment is effective.

---

Q: What is the shelf life of Lyderm cream?

The shelf life of the product is determined by the expiration date. According to official labeling, the expiration date for the Permethrin cream is printed on the tube and the outer carton. It is important to store the product according to the directions on the label until that date.

---

Q: Is Permethrin available as an oral tablet?

Permethrin is the active ingredient in an antiparasitic treatment. However, official regulatory and pharmacological information indicates that it is approved only as a topical preparation (a cream or a lotion) for external use. Regulatory documents indicate it is not approved as an oral tablet.

---

Q: What are the common trade names for Permethrin besides Lyderm?

Permethrin is the active ingredient in many treatments for parasitic infestations. Some of the other common brand names for topical Permethrin found in regulatory indices include Elimite, Acticin, and Nix.

Storage and Handling Requirements

Lyderm (Permethrin cream 5%) must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product should be kept in its original container to maintain its quality. As a mandatory requirement, this and all medicines must be stored out of the sight and reach of children.

Official Disposal Instructions

To dispose of unused or expired Permethrin cream, the product must not be flushed down a toilet or poured down a sink drain. Consumers should utilize a community drug take-back program if one is available. If a take-back program is not accessible, the product must be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash, following official guidelines.